Effect of Topical Simvastatin Therapy on Patients with Psoriasis
Keywords:Simvastatin ointment , psoriasis, Topical steroid.
Objective: Study the effect of simvastatin ointment on tissue expression of inflammatory mediators associated with pathogenesis of Psoriasis such as TNF-?, , IL-6 and ICAM-1. Background: Psoriasis is a common and complex inflammatory disease, which was described as the chronic systemic T-cell-mediated inflammatory condition characterized by the skin and joint manifestation. The patients with psoriasis are usually presented with a white-silvery scaly lesion covering various parts of the body. In psoriatic lesions, epidermal Keratinocytes produce a variety of inflammatory mediators, such as TNF-?, IL-6, ICAM-1 will stimulate the abnormal proliferation which will cause the psoriasis characteristics to appear. Simvastatin is an anti-hyperlipidemic agent that acts by competitive, reversible inhibition of the HMG-CoA, the rate-limiting step in cholesterol biosynthesis. Materials and Method: The study has been carried out on 44 patients suffering from mild to moderate chronic plaque psoriasis; patients with plaque psoriasis will be randomly divided into two groups, the first group was the Placebo group (n 22) whose patients have directed to have placebo plus topical steroid (Dermosalic ointment) ® ( Betamethasone dipropionate 0.5 mg /g and salicylic acid 30 mg /g) two times for a period of 8 weeks. The second group was the Simvastatin group (n-22) whose patients have been directed to have Simvastatin ointment 5% two times per day in addition to (Dermosalic ointment)® ( Betamethasone dipropionate 0.5 mg /g and salicylic acid 30 mg /g) for a period of 8 weeks. Before and after the eight weeks; The skin biopsy samples have been taken from patients in the two groups at baseline and after eight weeks of treatment used to measure concentrations of TNF-?, IL-6, and ICAM-1. Conclusion: The present study indicated the fact that Simvastatin ointment plus topical steroid improvement of psoriasis by reduce concentration of inflammatory mediators.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions